Mechanisms of cytostatic activity of new purine analogues;Mechanizmy działania cytostatycznego nowych analogów puryn

Nowotwory

Volumn 50, Issue 5, 2000, Pages 523-527

  Szmigielska Kaplon, A ^a   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Cladribine; Deoxycoformycin; Fludarabine; Mechanism of action; Purine analogues

Indexed keywords

CLADRIBINE; FLUDARABINE; PENTOSTATIN; PURINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; CYTOSTASIS; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; NONHODGKIN LYMPHOMA; REVIEW;

EID: 0034521625     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Studies of 9D-arabinofuranosyladenine in man
2. Adenosine deaminase deficiency in two patientes with severly impaired cellular immunity
3. Human adenosine deaminase, distribution and properties
4. Nucleosides of 2-fluoroadenine
5. Cladribine (2-chlorodeoxyadenosine)
6. 2-Chlorodeoxyadenosine: Drug development priorities
7. Fludarabine: Pharmacokinetics, mechanisms of action and rationales for combination therapies
8. On the pharmacokinetics of 2-chlorodeoxyadeosine in humans
9. Plasma and cellular bioavailability of oral fludarabine
10. Purine metabolism as a target for leukemia chemotherapy
11. Relationship of deoxycytydine kinase and cytoplasmic 5′nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine
12. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias
13. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic and molecular interactions
14. Present status of purine analogs in the therapy of chronic lymphocytic leukemias
15. Cladribine with prednisone versus chlorambucil with prednisone as first line therapy in chronic lymphocytic leukemia - Report of prospective randomized multicenter trial
16. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7 year experience in Poland
17. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - Updated results of the multicentre study of 378 patients
18. 2-Chlorodeoxyadenosine treatment of low -grade lymphomas
19. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
20. Long- term follow -up of patients with chronic lypmhocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
21. Activity of fludarabine in previously treated nonHodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group Study
22. The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype
23. High complete remission rate from 2-chlorodeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia; response predicted by rapid decrease of blood lymphocyte count
24. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chlorodeoxyadenosine and 9D arabinosylfluoroadenine
25. Apoptotic cell death in chronic lymphocytic leukemia
26. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells
27. P53,mdm-2,bax and bcl-2 and drug resistance in chronic lymphocytic leukemia
28. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine
29. Dr. Josef Steiner cancer research prize lecture: The role of physiological cell death in neoplastic transformation and in anti-cancer therapy
30. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
31. P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
32. P53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis
33. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
34. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukemia
35. Purine analogues kill resting lymphocytes by p53- dependent and -independent mechanisms
36. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 mutation and bcl-2 / bax proteins in drug resistance
37. Bcl-2 and bcl-xl antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents
38. Bax directly induces release of cytochrome c from isolated mitochondria
39. Deficient activation of CD95 (APO-1/Fas) system in drug -resistant cells